STAGE II PANCREATIC CANCER AJCC V8

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…

This study is testing a drug called talazoparib in people with advanced solid tumors that have specific DNA repair gene mutations. The goal is to see if this PARP inhibitor can shrink tumors or slow their growth, even in patients who have already tried a similar drug. About 36 ad…

This study tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The trial compares the higher-dose radiation to standard care, which may include more che…

This early-stage trial is testing whether combining a targeted drug (olaparib), an immunotherapy (durvalumab), and radiation therapy is safe for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study enrolls 18 adults who have already received…

This study tests a drug called pemigatinib in people with advanced or metastatic pancreatic cancer that has certain changes in the FGFR gene. The drug aims to block these abnormal genes and stop tumor growth. About 40 adults will take part entirely from home using telemedicine. T…

This study tests whether giving a combination of three chemotherapy drugs (gemcitabine, cisplatin, and nab-paclitaxel) before surgery can help shrink pancreatic tumors and improve outcomes. It is for people with pancreatic cancer that can be removed or is borderline removable. Th…

This study tests a new approach for people with pancreatic cancer that cannot be surgically removed. It combines a light-activated drug (verteporfin) with an immunotherapy (pembrolizumab) and standard chemotherapy. The goal is to see if this combination can shrink tumors better t…

This study is for people with pancreatic cancer that can be removed by surgery or has spread. Researchers want to see how different drugs change tumor biology by comparing biopsies taken before and after treatment. The goal is not to cure the disease now, but to learn which drugs…

This early phase 1 trial is studying how the drug OMO-103 affects pancreatic cancer cells in 12 patients with advanced or metastatic disease. The main goal is to see if the drug causes measurable changes in the tumor's biology by comparing tissue samples taken before and after tr…